Valproate inhibits colon cancer growth through cell cycle modification in vivo and in vitro

Experimental and Therapeutic Medicine

Volumn 2, Issue 2, 2011, Pages 301-307

  Strey, Christoph W ^a   Schamell, Lea ^a   Oppermann, Elsie ^a   Haferkamp, Axel ^a   Bechstein, Wolf O ^a   Blaheta, Roman A ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

Colorectal cancer; Histone deacetylase inhibition; Tumor cell lines; Valproic acid

Indexed keywords

CYCLIN D; CYCLIN DEPENDENT KINASE 1; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 4; CYCLIN E; HISTONE DEACETYLASE 3; HISTONE DEACETYLASE 4; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P19; PROTEIN P21; PROTEIN P27; VALPROIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER INHIBITION; CELL CYCLE; CELL CYCLE ARREST; CELL CYCLE PROGRESSION; CELL PROLIFERATION; COLORECTAL CANCER; DOSE RESPONSE; DOWN REGULATION; FEMALE; HISTONE ACETYLATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PROTEIN EXPRESSION; TUMOR GROWTH; TUMOR XENOGRAFT; UPREGULATION;

EID: 79551649914     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2011.202     Document Type: Article

References (34)

1. Taunton J, Hassig CA and Schreiber SL: A mammalian histone deacetylase related to the yeast transcriptional regulator Rpd3p. Science 272: 408-411, 1996.
2. Gurvich N, Tsygankova OM, Meinkoth JL and Klein PS: Histone deacetylase is a target of valproic acid-mediated cellular differentiation. Cancer Res 64: 1079-1086, 2004.
3. Gottlicher M, Minucci S, Zhu P, et al: Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J 20: 6969-6978, 2001.
4. Kuendgen A and Gattermann N: Valproic acid for the treatment of myeloid malignancies. cancer 110: 943-954, 2007.
5. Jones J, Juengel E, Mickuckyte A, Hudak L, Wedel S, Jonas D and Blaheta RA: The histone deacetylase inhibitor valproic acid alters growth properties of renal cell carcinoma in vitro and in vivo. J Cell Mol Med 13: 2376-2385, 2009.
6. Tan J, Cang S, Ma Y, Petrillo RL and Liu D: Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents. J Hematol Oncol 3: 5, 2010.
7. Lea MA, Ibeh C, Shah N and Moyer MP: Induction of differentiation of colon cancer cells by combined inhibition of kinases and histone deacetylase. Anticancer Res 27: 741-748, 2007.
8. Huang X and Guo B: Adenomatous polyposis coli determines sensitivity to histone deacetylase inhibitor-induced apoptosis in colon cancer cells. Cancer Res 66: 9245-9251, 2006.
9. Friedmann I, Atmaca A, Chow KU, Jager E and Weidmann E: Synergistic effects of valproic acid and mitomycin C in adeno-carcinoma cell lines and fresh tumor cells of patients with colon cancer. J Chemother 18: 415-420, 2006.
10. Biran A, Brownstein M, Haklai R and Kloog Y: Downregulation of survivin and aurora A by histone deacetylase and RAS inhibitors: a new drug combination for cancer therapy. Int J Cancer 128: 691-701, 2011.
11. Koyama M, Izutani Y, Goda AE, et al: Histone deacetylase inhibitors and 15-deoxy-Delta12,14-prostaglandin J2 synergistically induce apoptosis. Clin Cancer Res 16: 2320-2332, 2010.
12. Muller S and Kramer OH: Inhibitors of HDACs - effective drugs against cancer? Curr Cancer Drug Targets 10: 210-228, 2010.
13. Fedier A, Dedes KJ, Imesch P, von Bueren AO and Fink D: The histone deacetylase inhibitors suberoylanilide hydroxamic (Vorinostat) and valproic acid induce irreversible and MDR1-independent resistance in human colon cancer cells. Int J Oncol 31: 633-641, 2007.
14. Weichert W, Roske A, Niesporek S, et al: class I histone deacety-lase expression has independent prognostic impact in human colorectal cancer: specific role of class I histone deacetylases in vitro and in vivo. Clin Cancer Res 14: 1669-1677, 2008.
15. Venkataramani V, Rossner C, Iffland L, et al: Histone deacetylase inhibitor valproic acid inhibits cancer cell proliferation via down-regulation of the Alzheimer amyloid precursor protein. J Biol Chem 285: 10678-10689, 2010.
16. Spurling CC, Godman CA, Noonan EJ, Rasmussen TP, Rosenberg DW and Giardina C: HDAC3 overexpression and colon cancer cell proliferation and differentiation. Mol carcinog 47: 137-147, 2008.
17. Chavez-Blanco A, Perez-Plasencia C, Perez-cardenas E, et al: Antineoplastic effects of the DNA methylation inhibitor hydrala-zine and the histone deacetylase inhibitor valproic acid in cancer cell lines. Cancer Cell Int 6: 2, 2006.
18. Satyanarayana A and Kaldis P: Mammalian cell-cycle regulation: several Cdks, numerous cyclins and diverse compensatory mechanisms. Oncogene 28: 2925-2939, 2009.
19. Liu N, Fang H, Li Y and Xu W: Recent research in selective cyclin-dependent kinase 4 inhibitors for anti-cancer treatment. Curr Med Chem 16: 4869-4888, 2009.
20. Hanashiro K, Kanai M, Geng Y, Sicinski P and Fukasawa K: Roles of cyclins A and E in induction of centrosome amplification in p53-compromised cells. Oncogene 27: 5288-5302, 2008.
21. Yamamoto M, Tamakawa S, Yoshie M, Yaginuma Y and Ogawa K: Neoplastic hepatocyte growth associated with cyclin D1 redistribution from the cytoplasm to the nucleus in mouse hepatocarcinogenesis. Mol Carcinog 45: 901-913, 2006.
22. Mejlvang J, Kriajevska M, Vandewalle C, et al: Direct repression of cyclin D1 by SIP1 attenuates cell cycle progression in cells undergoing an epithelial mesenchymal transition. Mol Biol cell 18: 4615-4624, 2007.
23. Klein EA and Assoian RK: Transcriptional regulation of the cyclin D1 gene at a glance. J Cell Sci 121: 3853-3857, 2008.
24. Rampalli S, Pavithra L, Bhatt A, Kundu TK and Chattopadhyay S: Tumor suppressor SMAR1 mediates cyclin D1 repression by recruitment of the SIN3/histone deacetylase 1 complex. Mol Cell Biol 25: 8415-8429, 2005.
25. Sherr CJ and Roberts JM: CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev 13: 1501-1512, 1999.
26. Weber HO, Samuel T, Rauch P and Funk JO: Human p14 (ARF)-mediated cell cycle arrest strictly depends on intact p53 signaling pathways. Oncogene 21: 3207-3212, 2002.
27. Matheu A, Klatt P and Serrano M: Regulation of the INK4a/ ARF locus by histone deacetylase inhibitors. J Biol Chem 280: 42433-42441, 2005.
28. Hecker RM, Amstutz RA, Wachtel M, Walter D, Niggli FK and Schafer BW: p21 Downregulation is an important component of PAX3/FKHR oncogenicity and its reactivation by HDAC inhibitors enhances combination treatment. Oncogene 29: 3942-3952, 2010.
29. Lee S, Park JR, Seo MS, et al: Histone deacetylase inhibitors decrease proliferation potential and multilineage differentiation capability of human mesenchymal stem cells. cell Prolif 42: 711-720, 2009.
30. Wilson AJ, Byun DS, Nasser S, et al: HDAC4 promotes growth of colon cancer cells via repression of p21. Mol Biol Cell 19: 4062-4075, 2008.
31. Toyoshima H and Hunter T: p27, a novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21. Cell 78: 67-74, 1994.
32. Edgar BA and Orr-Weaver TL: Endoreplication cell cycles: more for less. Cell 105: 297-306, 2001.
33. Freidkin I, Herman M, Tobar A, chagnac A, Ori Y, Korzets A and Gafter U: Effects of histone deacetylase inhibitors on rat mesangial cells. Am J Physiol Renal Physiol 298: F426-F434, 2010.
34. Ziauddin MF, Yeow WS, Maxhimer JB, et al: Valproic acid, an antiepileptic drug with histone deacetylase inhibitory activity, potentiates the cytotoxic effect of Apo2L/TRAIL on cultured thoracic cancer cells through mitochondria-dependent caspase activation. Neoplasia 8: 446-457, 2006.